AstraZeneca Pharma India FY26: 33% revenue growth details

AstraZeneca Pharma India reports FY26 growth

AstraZeneca Pharma India Limited announced its full-year results for the financial year ended 31 March 2026, reporting a 33% year-on-year rise in total revenue. The company disclosed that total revenue from operations reached INR 22,755.8 million in FY 2025-26. The update was shared from Bengaluru, alongside operational commentary pointing to performance across Oncology and Biopharmaceuticals and progress in Rare Disease. The company also highlighted a higher pace of regulatory clearances during the year, reflecting expansion in its portfolio and patient access efforts. Separately, the broader AstraZeneca group reiterated its FY 2026 guidance after reporting Q1 2026 numbers globally.

FY 2025-26 numbers: revenue, profit and Q4 snapshot

For the quarter ended January to March 2026 (Q4), AstraZeneca Pharma India reported revenue from operations of INR 5,786.1 million. Profit before exceptional item and tax for Q4 stood at INR 592.2 million, while profit after exceptional item and tax was INR 448.8 million.

For the full FY 2025-26 period (April 2025 to March 2026), profit before exceptional item and tax was INR 2,574.5 million. Profit after exceptional item and tax for the year came in at INR 1,875.2 million. The company described the year as being supported by continued growth in Oncology and Biopharmaceuticals, along with progress in Rare Disease.

Board meeting and dividend recommendation

The company stated that its board approved audited financial results for the quarter and financial year ended March 31, 2026 on May 26, 2026. The board meeting commenced at 2:15 p.m. and concluded at 5:10 p.m. IST.

The board also recommended a dividend of Rs 36 per equity share of Rs 2 face value for FY2026, subject to shareholder approval. The company added that the statutory auditors’ report on the audited FY2026 financial results carried an unmodified opinion.

Q1 performance: FY25-26 shows sharp year-on-year rise

For the quarter ended June 30, 2025 (Q1 FY25-26), AstraZeneca Pharma India reported that revenue increased 36% compared with the same period last year. Total revenue from operations in Q1 FY25-26 was INR 5,263.1 million versus INR 3,875.2 million in Q1 FY24.

Profit before exceptional item and tax for Q1 FY25-26 was INR 750.6 million, compared with INR 424.0 million a year earlier. Profit after exceptional item and tax was INR 558.3 million, compared with a loss of INR 117.9 million in Q1 FY24. The company linked the prior-year loss to provisions associated with the exit of a factory site that was announced in that quarter.

Operating line items referenced in the Q1 results table

A separate quarterly table (figures referenced in INR million) showed total revenue of INR 5,263.1 million for the period labelled Jun 25 and INR 5,786.1 million for the period labelled Mar 26. Operating income was listed as INR 641.8 million (Jun 25) and INR 542.3 million (Mar 26). Net income was listed as INR 558.3 million (Jun 25) and INR 448.9 million (Mar 26).

The same table reported total operating expense of INR 4,621.3 million (Jun 25) and INR 5,243.8 million (Mar 26), and selling, general and admin expenses total of INR 886.8 million (Jun 25) and INR 840.0 million (Mar 26). Diluted normalized EPS was listed as 22.44 (Jun 25) and 18.28 (Mar 26).

Regulatory approvals and portfolio expansion

AstraZeneca Pharma India said FY 2025-26 was marked by 11 new regulatory approvals for medicines and indications. It attributed this to its focus on scientific innovation and accelerated access to innovative medicines in India.

In the Q1 FY25-26 update, the company highlighted four CDSCO approvals. These included an additional indication for Osimertinib tablets in combination with pemetrexed and platinum-based chemotherapy for first-line treatment of locally advanced or metastatic non-small cell lung cancer with specified EGFR mutations. It also cited an additional indication for trastuzumab deruxtecan in HER2-low and HER2-ultralow metastatic breast cancer patients who have received at least one endocrine therapy in the metastatic setting. The company further noted an additional indication for Osimertinib as a monotherapy for locally advanced, unresectable stage III NSCLC with specified EGFR mutations whose disease has not progressed during or following platinum-based chemoradiation therapy. And it referenced an additional indication for Benralizumab as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis.

Key financial snapshot table (normalised to INR million)

Global AstraZeneca context: Q1 2026 and guidance reiterated

AstraZeneca also reported global Q1 2026 performance, stating that total Q1 revenue rose 8% to USD 15,288 million. It said the increase was driven by double-digit growth in Oncology and Rare Disease.

The group reconfirmed its Total Revenue and Core EPS guidance for FY 2026 at constant exchange rates, based on the average foreign exchange rates through 2025. It stated that total revenue is expected to increase by a mid-to-high single-digit percentage, and Core EPS is expected to increase by a low double-digit percentage. It also stated that the Core Tax rate is expected to be between 18% and 22%, with a Q1 core tax rate referenced at 21%.

Results calendar: upcoming disclosures

The company indicated it intends to publish its H1 and Q2 2026 results on 27 July 2026. It also listed prior milestones in its results calendar, including Q1 2026 results dated 29 April 2026 and full-year and Q4 2025 results dated 10 February 2026.

Market impact and why these updates matter

For investors tracking AstraZeneca Pharma India, the combination of FY25-26 revenue of INR 22,755.8 million and the board’s dividend recommendation provides two concrete signals: scale of operations and potential cash return, subject to shareholder approval. The FY25-26 profit after exceptional item and tax of INR 1,875.2 million also frames the company’s profitability for the year, alongside the Q4 contribution of INR 448.8 million.

Operationally, the company’s emphasis on approvals is relevant because it signals additions and expanded indications for its portfolio, particularly in Oncology. In the Q1 FY25-26 update, the company explicitly connected growth with regulatory milestones and portfolio expansion. Separately, the parent group’s reiterated FY 2026 guidance provides context on broader business momentum, but it is distinct from the India-listed entity’s reported INR-denominated performance.

Conclusion

AstraZeneca Pharma India’s FY25-26 results showed total revenue from operations of INR 22,755.8 million and profit after exceptional item and tax of INR 1,875.2 million, alongside a recommended dividend of Rs 36 per share. The company also reported 11 new regulatory approvals during the year and described strong Q1 FY25-26 momentum with 36% year-on-year revenue growth. The next key checkpoint on the calendar is the planned publication of H1 and Q2 2026 results on 27 July 2026.